Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin/kexin type 9.
about
Lipid-lowering efficacy of atorvastatinLipid lowering efficacy of atorvastatinAncestry and other genetic associations with plasma PCSK9 response to simvastatin.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat.Impacts of ezetimibe on PCSK9 in rats: study on the expression in different organs and the potential mechanisms.Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats.Proprotein Convertase Subtilisin/Kexin type 9, C-Reactive Protein, Coronary Severity, and Outcomes in Patients With Stable Coronary Artery Disease: A Prospective Observational Cohort Study.Enhanced circulating PCSK9 concentration by berberine through SREBP-2 pathway in high fat diet-fed ratsEffect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials.The Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Cardiovascular Homeostasis: A Non-Systematic Literature Review.Lipid Lowering Therapy and Circulating PCSK9 Concentration.HMGCR rs17671591 SNP Determines Lower Plasma LDL-C after Atorvastatin Therapy in Chilean Individuals.New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.Relation of resistin to proprotein convertase subtilisin-kexin type 9 levels in coronary artery disease patients with different nutritional status.Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease
P2860
Q24187301-734FF354-467B-4AEC-91AD-B6EFB6DE7C4BQ24202363-EE2529FD-466B-4E52-BB30-BB4A59AB809DQ34157965-F88D039D-9960-432A-897E-420B056A34D0Q34458693-8D98B64D-959F-4523-AFFC-1EDDC342CE12Q34789111-2747E506-1659-4E6B-9BBB-265B7769299CQ35194029-23F766DE-BC8C-45D7-B255-3C21B6EB4328Q36574008-96E31CC5-4900-480C-B6BF-AEC370A916E7Q37596775-0EF303BB-ED1B-423A-A616-2901C67E5C66Q37624278-45CA7126-78E0-4FD0-8C25-ED6472BD4DADQ37724743-A76AD620-034A-454C-AB11-34ADC20044E2Q38548750-D320A54B-E71B-42C5-983F-331745BDF32BQ38637552-AD877563-8FD3-47A9-B9D3-512C0412F944Q38643197-CB8B84CA-E61A-4F45-80FF-84F4D1448A75Q40499193-3FE3FA1F-F843-49CC-B904-2E26F2759C46Q50044216-BC14ECEC-FFD4-4A40-9CA2-34A1307ECA39Q52941312-4FB4BFDB-3D51-41CF-8306-9AD6D0A1F127Q58258510-4718C68A-BC6B-4D7E-827C-2B3D8E99025A
P2860
Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin/kexin type 9.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Short-term impact of low-dose ...... rtase subtilisin/kexin type 9.
@en
Short-term impact of low-dose ...... rtase subtilisin/kexin type 9.
@nl
type
label
Short-term impact of low-dose ...... rtase subtilisin/kexin type 9.
@en
Short-term impact of low-dose ...... rtase subtilisin/kexin type 9.
@nl
prefLabel
Short-term impact of low-dose ...... rtase subtilisin/kexin type 9.
@en
Short-term impact of low-dose ...... rtase subtilisin/kexin type 9.
@nl
P2093
P2860
P1476
Short-term impact of low-dose ...... rtase subtilisin/kexin type 9.
@en
P2093
Cheng-Gang Zhu
Jian-Jun Li
Li-Xin Jiang
Na-Qiong Wu
Rui-Xia Xu
Yuan-Lin Guo
P2860
P304
P356
10.1007/S40261-013-0129-2
P577
2013-12-01T00:00:00Z